anti-CD20/CD30-CAR-T cells

BIOLOGICAL2 trials

Sponsors

Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai First Song Biotechnology Co., LTD

Conditions

B Cell MalignanciesRelapsed/Refractory Lymphoma

Early Phase 1

An Exploratory Clinical Study Evaluating the Safety and Efficacy of Intravenous Anti-CD20/CD30-CAR-T Cell Infusion in Relapsed/Refractory Lymphoma Patients.

Not yet recruitingNCT06519344

Shanghai Tongji Hospital, Tongji University School of MedicineB Cell Malignancies

Start: 2024-07-31End: 2027-07-30Target: 12Updated: 2024-07-25

Safety and Efficacy of Anti-CD20/CD30 CAR-T Cells in Subjects with Relapsed/Refractory Lymphoma

RecruitingNCT06532643

Shanghai First Song Biotechnology Co., LTDRelapsed/Refractory Lymphoma

Start: 2023-08-24End: 2026-09-01Target: 9Updated: 2024-09-19